TLDR Weight-loss drugs are not linked to suicidal thoughts.
A review by the FDA found no evidence linking GLP-1 receptor agonists, a class of weight-loss and diabetes drugs, to suicidality. An independent large clinical trial with over 105,000 participants showed that those taking semaglutide were 27% less likely to experience initial suicidal ideation compared to those on non-GLP-1 obesity medications. The FDA continues to monitor for potential risks, including suicidal thoughts, aspiration, and alopecia. Psychiatrists are encouraged to play a more active role in managing obesity, especially in patients with serious mental illness, by incorporating holistic weight management plans and collaborating with specialists. Despite the benefits, high costs of these medications remain a significant barrier.
11 citations,
December 2022 in “Arterial Hypertension” New guidelines stress early diagnosis and lifestyle changes to manage metabolic syndrome and prevent complications.
2 citations,
December 2022 in “Journal of Clinical Medicine” Medications for glucose metabolism and weight control, combined therapy options, and herbal medicines may help regulate menstrual cycle in adolescents with PCOS.
20 citations,
August 2022 in “Archives of Medical Science” The Polish medical societies have redefined metabolic syndrome and recommend lifestyle changes, certain medications, and possibly bariatric surgery for treatment. They also discuss managing related health conditions.
July 2023 in “Journal of Clinical Medicine” Tirzepatide might help manage PCOS in obese patients but needs more research to confirm safety and effectiveness.
1 citations,
March 2023 in “Nutrients” The conclusion is that obesity should be managed with a slow, balanced approach to diet and exercise, with medication and surgery as additional options, and education and access to care are important.
